Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuko Yoshio

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Cancers|February 10, 2024
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCaKoji Mita, Kouji Izumi, Akihiro Goriki, et al.
Cancer Immunology, Immunotherapy : CII|July 8, 2021
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLRTakashi Kobayashi, Katsuhiro Ito, Takahiro Kojima, et al.
Scientific Reports|July 3, 2024
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancerShinichi Sakamoto, Kodai Sato, Takahiro Kimura, et al.
Journal of Geriatric Oncology|July 9, 2021
Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matchingNaotaka Nishiyama, Takashi Kobayashi, Shintaro Narita, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Cancers|February 10, 2024
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCaKoji Mita, Kouji Izumi, Akihiro Goriki, et al.
Cancer Immunology, Immunotherapy : CII|July 8, 2021
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLRTakashi Kobayashi, Katsuhiro Ito, Takahiro Kojima, et al.
Scientific Reports|July 3, 2024
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancerShinichi Sakamoto, Kodai Sato, Takahiro Kimura, et al.
Journal of Geriatric Oncology|July 9, 2021
Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matchingNaotaka Nishiyama, Takashi Kobayashi, Shintaro Narita, et al.
Pageof 4